Drug Trial Radar · NCT03288493
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Last checked: Nov 20, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
105
Actual
Start
Sep 20, 2017
Primary completion
Apr 27, 2022
Study completion Apr 27, 2022
Sponsor
- Lead sponsor
- Poseida Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- California Institute for Regenerative Medicine (CIRM)
- First posted
- Sep 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Conditions
- Multiple Myeloma
Interventions
P-BCMA-101 CAR-T cellsBiological
P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated.
RimiducidDrug
Rimiducid (safety switch activator) may be administered as indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Assess the Safety of P-BCMA-101Time frame: Baseline through Day 28
- Phase 1: Maximum Tolerated Dose of P-BCMA-101Time frame: Baseline through Day 28
- Phase 2: Assess the Safety of P-BCMA-101Time frame: Baseline through 24 months
- Phase 2: Assess the Efficacy of P-BCMA-101 (ORR)Time frame: Baseline through 24 months
- Phase 2: Assess the Efficacy of P-BCMA-101 (DOR)Time frame: Baseline through 24 months
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
University of California Davis
Davis, California
University of California San Diego
San Diego, California
University of California San Francisco
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
University of Chicago
Chicago, Illinois
University of Kansas Cancer Center
Westwood, Kansas
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Wayne State - Karmanos Cancer Institute
Detroit, Michigan
John Theurer Cancer Center
Hackensack, New Jersey
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Swedish Cancer Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.